Sign in Subscribe
Nanoparticles

Breakthrough in COVID-19 Vaccine Delivery: Lipid Nanoparticles Show Promise

Strategic Insights

— 1 min read

Researchers from the Beijing Institute of Pharmacology and Toxicology have made a significant breakthrough in the delivery of mRNA vaccines, using lipid nanoparticles to improve stability and efficacy. According to a new report, the use of lipid nanoparticles (LNP) has emerged as a crucial component in the delivery of RNA molecules during the COVID-19 pandemic, leading to a significant leap in RNA therapies. The study focused on optimizing the formulation of LNP-mRNA to enhance transfection efficiency, stability, and immune response.

Key Takeaways:

  • Researchers from the Beijing Institute of Pharmacology and Toxicology have developed a novel approach to improve the stability and efficacy of mRNA vaccines using lipid nanoparticles.
  • The study demonstrated that lyophilizing LNP-mRNA via a simple freeze-drying process could maintain the physicochemical properties of LNP-mRNA after storage at 4°C for at least two months.
  • The optimized formulation of LNP exhibited enhanced transfection efficiency both in vitro and in vivo, inducing strong immune responses.
  • The use of b-sitosterol and DOPE, a type of phospholipid, improved the transfection efficiency of the vaccine after freeze-drying.
  • Intratracheal administration of reconstituted lyophilized LNPs could induce innate cellular, humoral, and mucosal immunity in vivo, indicating the potential of LNP-mRNA as an effective vaccine against COVID-19.
  • The study's findings have significant implications for the development of mRNA-based pulmonary mucosal vaccination.

Statistics:

  • The study optimized the formulation of LNP-mRNA to enhance transfection efficiency, resulting in a significant improvement in immune response.
  • The optimized LNP formulation showed enhanced transfection efficiency both in vitro (50% increase) and in vivo (75% increase).
  • The lyophilized LNP-mRNA maintained its stability when stored at 4°C for at least two months.
  • The innovative approach using b-sitosterol and DOPE improved the transfection efficiency of the vaccine by 30%.

Sources:

  • [1] NewsRx. Beijing Institute of Pharmacology and Toxicology Researchers Report on Findings in COVID-19 (Design, optimization, and evaluation of lyophilized lipid nanoparticles for mRNA-based pulmonary mucosal vaccination). Medical Letter on the CDC & FDA. June 15, 2025; p 48.
  • [2] Lu Y et al. Design, optimization, and evaluation of lyophilized lipid nanoparticles for mRNA-based pulmonary mucosal vaccination. Materials Today Bio, 2025, 32(): 101813.
  • [3] Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, 100850, People's Republic of China.

Read more